v3.26.1
Note 11 - Stock-Based Compensation - Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2026
Dec. 31, 2025
Outstanding, options (in shares) 10,272,642  
Oustanding, weighted average exercise price (in dollars per share) $ 1.62  
Outstanding, remaining contractual term (Year) 7 years 7 months 6 days [1] 7 years 6 months
Outstanding, intrinsic value [2] $ 472 [1] $ 396
Granted, options (in shares) [3] 2,228,500  
Granted, weighted average exercise price (in dollars per share) [3] $ 1.35  
Exercised, options (in shares) (15,157)  
Exercised, weighted average exercise price (in dollars per share) $ 1.29  
Forfeited, options (in shares) (132,443)  
Forfeited, weighted average exercise price (in dollars per share) $ 1.33  
Outstanding, options (in shares) 12,353,542 [1] 10,272,642
Oustanding, weighted average exercise price (in dollars per share) $ 1.57 [1] $ 1.62
Vested and exercisable, options (in shares) 7,680,579  
Vested and exercisable, weighted average exercise price (in dollars per share) $ 1.74  
Vested and exercisable, remaining contractual term (Year) 6 years 7 months 6 days  
Vested and exercisable, intrinsic value [2] $ 402  
[1] The outstanding stock options presented in the table above are inclusive of 523,300 stock options granted outside the Lucid Diagnostics 2018 Equity Plan, as of March 31, 2026 and December 31, 2025.
[2] The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of March 31, 2026 and December 31, 2025 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price.
[3] Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.